Mitochondrial myopathy without extraocular muscle involvement: a unique clinicopathologic profile

J Neurol. 2024 Feb;271(2):864-876. doi: 10.1007/s00415-023-12005-5. Epub 2023 Oct 17.

Abstract

Objective: Mitochondrial myopathy without extraocular muscles involvement (MiMy) represents a distinct form of mitochondrial disorder predominantly affecting proximal/distal or axial muscles, with its phenotypic, genotypic features, and long-term prognosis poorly understood.

Methods: A cross-sectional study conducted at a national diagnostic center for mitochondrial disease involved 47 MiMy patients, from a cohort of 643 mitochondrial disease cases followed up at Qilu Hospital from January 1, 2000, to January 1, 2021. We compared the clinical, pathological, and genetic features of MiMy to progressive external ophthalmoplegia (PEO) and mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) patients.

Results: MiMy patients demonstrated a more pronounced muscle involvement syndrome, with lower 6MWT scores, higher FSS, and lower BMI compared to PEO and MELAS patients. Serum levels of creatinine kinase (CK), lactate, and growth and differentiation factor 15 (GDF15) were substantially elevated in MiMy patients. Nearly a third (31.9%) displayed signs of subclinical peripheral neuropathy, mostly axonal neuropathy. Muscle biopsies revealed that cytochrome c oxidase strong (COX-s) ragged-red fibers (RRFs) were a typical pathological feature in MiMy patients. Genetic analysis predominantly revealed mtDNA point pathogenic variants (59.6%) and less frequently single (12.8%) or multiple (4.2%) mtDNA deletions. During the follow-up, a majority (76.1%) of MiMy patients experienced stabilization or improvement after therapeutic intervention.

Conclusions: This study provides a comprehensive profile of MiMy through a large patient cohort, elucidating its unique clinical, genetic, and pathological features. These findings offer significant insights into the diagnostic and therapeutic management of MiMy, ultimately aiming to ameliorate patient outcomes and enhance the quality of life.

Keywords: Clinicopathologic features; MELAS; MiMy; Mitochondrial disorders; PEO.

MeSH terms

  • Acidosis, Lactic*
  • Cross-Sectional Studies
  • DNA, Mitochondrial / genetics
  • Humans
  • MELAS Syndrome* / genetics
  • Oculomotor Muscles
  • Ophthalmoplegia, Chronic Progressive External* / genetics
  • Ophthalmoplegia, Chronic Progressive External* / pathology
  • Quality of Life
  • Stroke* / pathology

Substances

  • DNA, Mitochondrial